News | December 19, 2024
Cipla launches India's first inhalable insulin ‘Afrezza’
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
Merck has also decided to end the favezelimab clinical development program
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Final decision from the European Commission is anticipated within the coming months
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Subscribe To Our Newsletter & Stay Updated
